Sir, Chédiak-Higashi syndrome (CHS) is an autosomal recessive disorder, caused by mutations in CHS1 (also known as LYST gene) located on band 1q42-43. This gene encodes a protein called lysosomal trafficking regulator, which regulates the synthesis, transport, and fusion of cytoplasmic vesicles. Mutations of this gene result in a defect in granule morphogenesis in multiple tissues causing grossly enlarged and nonfunctional lysosomes, which are identified during the cytological examination as a giant, coalesced, azurophilic granules present in multiple systemic and neurological tissues. These granules are specific to CHS and their presence in granulocytes from peripheral blood and bone marrow forms a basis of clinical diagnosis. CHS patients with deletions in the CHS1 gene usually present with a fulminant-accelerated phase early in life. [1, 2] CHS was first described by Beguez-Cesar in 1943 in three siblings with neutropenia and abnormal granules in leukocytes; and later by Chédiak (1952), a Cuban hematologist; and Higashi (1954), a Japanese pediatrician. [2] CHS is often diagnosed during the first decade of life. CHS affects multiple organs and body systems; and is characterized by frequent infections, oculocutaneous albinism (OCA), bleeding diathesis, with progressive neurological deterioration. Death often occurs early either due to infection, bleeding, or development of HLH (Hemophagocytic Lymphohistiocytosis). [1, 2] Fewer than 500 cases of CHS have been reported worldwide over the last 20 years, [1] and studies documenting neuroimaging findings in the accelerated phase of CHS are still few. We describe the typical and novel neuroradiological findings in CHS while reviewing the literature and discussing other relevant differentials.
case RepoRt
A six-year-old male child born of second-degree consanguineous parentage (parents were first cousins) was brought with recurrent febrile episodes, abnormal gait, and "weakness of limbs". On examination, the child was found to have oculocutaneous albinism (OCA), hepatosplenomegaly, and generalized lymphadenopathy. His neurological examination was notable of marked ataxia, long-tract signs, ocular nystagmus, and clinical features suggestive of peripheral neuropathy (wrist and foot drop with global areflexia). He had an unremarkable birth and developmental history until 1 year of age. There was no significant family history of similar or other neurological illnesses. He became symptomatic since 1 year of age. On hematological evaluation, he was found to have pancytopenia; bone marrow revealed hemophagocytic lymphohistiocytosis (HLH) with giant granules typically suggestive of CHS [ Figure 1 ]. His creatinine phosphokinase enzyme and hepatic and renal functions were normal. TORCH (toxoplasmosis, rubella cytomegalovirus, herpes simplex, and human immunodeficiency virus; HIV) profile and HIV serology were negative, however, serum Ebstein Barr Virus (EBV) antibody was positive. Nerve conduction study showed severe axonal neuropathy. A magnetic resonance imaging (MRI) of the brain revealed a very striking picture [ Figure 2a -g] with symmetrical, bilateral confluent, white matter hyperintensities, on T2-weighted images, in cerebral and cerebellar hemispheres. The subcortical U-fibers were spared. Bilateral globus pallidi were hyperintense on T2-weighted images. There was no parenchymal contrast-enhancement noted. Diffuse diffusion restriction in the cerebellum with a relatively lower apparent diffusion coefficient (ADC) values compared to cerebral hemispheres were also noted. Magnetic resonance spectroscopy (MRS) showed a Choline peak. MRI of the spine was unremarkable, although significant hepatosplenomegaly and lymphadenopathy were noted [ Figure 3 ]. A study of the cerebrospinal fluid showed pleocytosis with elevated proteins. However, CSF study for viruses, fungi, and bacteria was negative. CHS1 gene testing with next-generation sequencing (NGS) confirmed a pathogenic heterozygous mutation on exon 5 of the CHS1 gene. A diagnosis of CHS with accelerated phase was made. Systemic immunosuppressant therapy (steroid) was initiated. Intrathecal methotrexate was advised for the CNS (central nervous system) HLH, which the family declined. The option of hematopoietic stem cell transplantation (HSCT) was also explained to the family with explicit counseling that the CNS disease would not reverse. Given the diagnosis of CHS in accelerated phase, there was a very high mortality rate at that point despite HSCT. Unfortunately, the child succumbed in 2 weeks while on medical therapy.
Novel MRI Finding of Bilateral Globus Pallidal Involvement in Accelerated Phase of Chédiak -Higashi Syndrome

dIscussIon
Neurological involvement in CHS commonly presents as ataxia, movement disorders, neuropathies, cranial nerve palsies, learning difficulty, and seizures. Neuro-ophthalmological involvement is usually in the form of iris hypopigmentation, decreased retinal pigmentation, photophobia, reduced visual acuity, nystagmus, and squint. [1] [2] [3] Patients, who survive to second or third decade, may exhibit neurological deterioration including Parkinsonism and dementia, and become wheelchair bound. [3] Similar to our case, 85% of CHS patients develop accelerated phase or HLH with CNS involvement. This phase is characterized by pancytopenia, high-grade fever, lymphohistiocytic infiltration of multiple organs. Treatment of accelerated-phase CHS is difficult and prognosis remains poor, often fatal if not treated in a timely manner. [2] HLH often occurs following initial exposure to EBV, [4] as the case was in this child. Our case had bilateral global pallidal involvement with striking cerebellar involvement in the form of diffuse cerebellar diffusion restriction in addition, to the supratentorial white matter involvement described previously. While the low ADC values in the cerebellum were not suggestive of ischemia, this finding as well as other findings we describe, are explained by an extensive and wide-spread inflammatory process seen in the accelerated phase of CHS.
Neuroimaging features of CHS are variable and discordant. [5] Rego et al. described three predominant patterns of neuroparenchymal involvement: Diffuse, focal, and mixed diffuse/focal. [6] Our case had a later pattern (mixed). Neuroimaging findings in CHS reported in the literature include supratentorial neoplasm-like contrast-enhancing masses, diffuse brain parenchymal atrophy, cerebellar atrophy, T2 hyperintensities in periventricular and corona radiata regions. [6] Diffuse brain atrophy, T2 signal hyperintensity with no contrast enhancement was demonstrated in periventricular and corona radiata regions in another case report. [7] Isolated cerebellar atrophy has also been reported in an older patient of 20 years. [8] . More recently, Lolli et al. reported symmetrical, punctate, and curvilinear gadolinium enhancement involving brainstem, pons, and extending variably to middle cerebellar peduncles and cerebellum. MRS changes in this study were suggestive of acute inflammation and demyelination with decreased NAA/Cr ratios, likely due to axonal damage and increased Cho/Cr ratios, similar to our case, reflecting glial proliferation and increased cellular membrane turnover in the proliferating astrocytes. [9] To our knowledge, deep grey involvement, as described in this case, in the accelerated phase of CHS is previously unreported in the literature.
These neuroradiological findings observed in CHS, are not only specific for CHS but may also be seen in other HLH syndromes with CNS involvement, all of which remain important differential diagnosis. This novel deep gray matter involvement in accelerated CHS is best postulated as caused by underlying pathogenesis involving variable degrees of lymphohistiocytic infiltration of the various neural tissues, starting with the white matter initially, and perhaps becoming more severe and extensive with disease severity. We hypothesize that the deep gray involvement of CNS seen on imaging in accelerated CHS is predictive of a malignant course with poor response to therapy. A similar finding has been reported in Griscelli Syndrome type II another HLH syndrome, [6] which remains one of the important differentials. Other clinicoradiological differentials with similar findings include Hermansky-Pudlak syndrome types 2 and 9, an immunodeficiency associated with mitogen-activated protein-binding protein (MAPBP) interacting protein.
These disorders also share similar cutaneous, hematological, and systemic features with CHS. [10] However, prominent neurological features in the form of cerebellar signs, neuropathy, corticospinal signs with laboratory markers such as presence of giant inclusions in peripheral or bone marrow smears, and genetic testing can help in the diagnosis of CHS; thus assisting in timely, aggressive treatment and prognostication, and also in genetic counseling, thereby, preventing familial recurrence of this severe disorder.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. 
Cervical Artery Dissection-Related Stroke: Vascular Risk Factors May Have a Role
Sir, Dissection is a relatively uncommon but important cause of stroke. The epidemiological data from a stroke registry in France suggest that they account for approximately 2% of all strokes and the incidence rate is 2.97/100,000/year. [1] Trauma, direct or indirect, is well known to be a trigger leading to cervical artery dissection-related stroke. But, is this dissection, more common in vessels, already exposed to vascular risk factors? There is a paucity of evidence to answer this question.
To address this gap in knowledge, we designed this study to document the presence of certain predefined risk factors in patients with extracranial cervical artery dissection causing stroke.
We carried out a retrospective and prospective observational study over a two-year period at a tertiary care referral center. Patients who were 18 years or older and with a confirmed diagnosis of ischemic stroke due to extracranial cervical (carotid or vertebral) artery dissection proven by angiography were included in the study. the presence or absence of the following risk factors were documented: History of unaccustomed physical activity or trauma in the preceding one week, history of cervical manipulation in the preceding two weeks, hypertension (treated or untreated), diabetes (treated or untreated), smoking, hypercholesterolemia (>200 mg/dL), overweight (BMI >27 kg/m 2 ), alcohol consumption at least once a week, coronary artery disease (CAD), migraine, family history of stroke, past history of stroke, and preceding infection in the previous week. Assuming from previous studies that 2% of all ischemic strokes are caused by dissection, an online sample size calculator for a descriptive study for dichotomous outcome variable was used. A sample size of 30 was estimated using level of confidence as 95% and absolute error of margin of 5%. Descriptive statistical analysis was carried out in the study. Data analysis was done using statistical package for social sciences Version 20.0. Prior clearance was taken from the institutional ethical committee. Informed written consent was taken from all patients or their next of kin.
A total of 30 patients with dissection and ischemic stroke were included in the study. Diagnosis of dissection was confirmed by digital subtraction angiography in 27 patients while magnetic resonance angiography was used to confirm in three patients. Twenty six (86.7%) were males. Mean age was 42.3 years (±10.1) with range of 23-67 years. Eighty percent (24) of the patients were below 50 years. Majority (52%) patients had the dissection in winter defined as November to February followed by monsoon (32%) defined as July to October. The dissection occurred in 11 (36.7%) patients in the carotid artery and 19 (63.3%) patients in the vertebrobasilar artery. Most common segment involved in vertebral artery dissection was V3 (45.8%) followed by V1 and V2 (20.8% each). Five patients had more than one vertebral artery segment involved. Isolated dissection of V4 did not occur. One patient had extension of vertebral artery dissection to basilar artery associated with subarachnoid hemorrhage and ischemic stroke. Most common site involved in carotid artery dissection was proximal extracranial internal carotid artery (90.9%). One patient had involvement of common carotid artery (9.1%). Headache and neck pain occurred in majority of patients. Cranial nerve deficit was noted in 66.7% of patients. All patients with carotid artery dissection had upper motor neuron seventh cranial nerve involvement. Nine patients (47.3%) with vertebrobasilar artery dissection had cranial nerve involvement. Eight of these (42.1%) had ninth and tenth involvement, four (21%) had lower motor neuron seventh involvement, three (15.7%) had fifth, and one each (5.2%) had sixth, eighth, and twelfth cranial nerve involved, respectively.
